RxDoctor Payments Data

Douglas Howerton, MD

Gastroenterology · Chesapeake, VANPI 1295734283

Payments from drug & device makers

$12,151in general payments, 2019–2025

Across 469 payments — averaging $25.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Johnson & Johnson$780
  • Takeda Pharmaceuticals U.S.A., Inc.$715
  • Ambu Inc.$705
  • Olympus America Inc.$677
  • Conmed Corporation$582
  • plus $5K from 38 others

What the payments were for

  • Travel & lodging$2952%
  • Food & beverage$11,79597%
  • Education$611%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,151 in reported general payments places this provider in the 75th percentile of 473 gastroenterology providers in Virginia.

See all gastroenterology providers in Virginia

Medicare billing

Part B allowed, 2024
$247,567
Medicare patients
824
Services billed
1,444

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab13$377,466
CreonLipase/Protease/Amylase17$37,072
LinzessLinaclotide23$20,215
Lansoprazole13$10,261
Mesalamine ErMesalamine19$4,582
Dexlansoprazole DrDexlansoprazole16$4,221
Esomeprazole Magnesium61$3,296
DexilantDexlansoprazole11$3,262
Budesonide DrBudesonide30$2,968
SutabSod Sulf/Pot Chloride/Mag Sulf14$2,247
Omeprazole155$1,940
Pantoprazole Sodium114$1,873
Colestipol Hcl35$1,820
Budesonide EcBudesonide19$1,748
Sucralfate18$1,546

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$780$377,46613 claims
AbbVieCreon, Linzess$3,485$57,28740 claims
Takeda Pharmaceuticals U.S.A., Inc.Dexilant$715$3,26211 claims
Braintree Laboratories, Inc.Sutab$13$2,24714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 473 gastroenterology providers in Virginia.

Other gastroenterology in Chesapeake

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →